BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 11904737)

  • 21. Increased leukocyte-endothelial interactions in syndecan-1-deficient mice involve heparan sulfate-dependent and -independent steps.
    Götte M; Bernfield M; Joussen AM
    Curr Eye Res; 2005 Jun; 30(6):417-22. PubMed ID: 16020273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein.
    Viklund L; Loo BM; Hermonen J; El-Darwish K; Jalkanen M; Salmivirta M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):146-52. PubMed ID: 11779146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-syndecan: structure and function of a transmembrane heparan sulfate proteoglycan.
    Carey DJ
    Perspect Dev Neurobiol; 1996; 3(4):331-46. PubMed ID: 9117264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors.
    Bernfield M; Sanderson RD
    Philos Trans R Soc Lond B Biol Sci; 1990 Mar; 327(1239):171-86. PubMed ID: 1969657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of syndecans in lymphoid systems].
    Sebestyén A; Kopper L
    Magy Onkol; 2001; 45(1):67-74. PubMed ID: 12050731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of syndecan-1 proteoglycan in the invasiveness of HT-1080 fibrosarcoma].
    Péterfia B; Hollósi P; Szilák L; Timár F; Paku S; Jeney A; Kovalszky I
    Magy Onkol; 2006; 50(2):115-20. PubMed ID: 16888674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9.
    Brule S; Charnaux N; Sutton A; Ledoux D; Chaigneau T; Saffar L; Gattegno L
    Glycobiology; 2006 Jun; 16(6):488-501. PubMed ID: 16513763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The expression, secretion and regulation of membrane-soluble syndecan-1 in human multiple myeloma cells].
    Li X; Lu Z; Klein B
    Zhonghua Xue Ye Xue Za Zhi; 2000 Nov; 21(11):572-6. PubMed ID: 11225246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation.
    Fisher MC; Li Y; Seghatoleslami MR; Dealy CN; Kosher RA
    Matrix Biol; 2006 Jan; 25(1):27-39. PubMed ID: 16226436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syndecan-4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes.
    Yamashita Y; Oritani K; Miyoshi EK; Wall R; Bernfield M; Kincade PW
    J Immunol; 1999 May; 162(10):5940-8. PubMed ID: 10229831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.
    Dhodapkar MV; Sanderson RD
    Leuk Lymphoma; 1999 Jun; 34(1-2):35-43. PubMed ID: 10350330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice.
    Alexander CM; Reichsman F; Hinkes MT; Lincecum J; Becker KA; Cumberledge S; Bernfield M
    Nat Genet; 2000 Jul; 25(3):329-32. PubMed ID: 10888884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
    Gulyás M; Hjerpe A
    J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Syndecan-2 expression in colorectal cancer-derived HT-29 M6 epithelial cells induces a migratory phenotype.
    Contreras HR; Fabre M; Granés F; Casaroli-Marano R; Rocamora N; Herreros AG; Reina M; Vilaró S
    Biochem Biophys Res Commun; 2001 Aug; 286(4):742-51. PubMed ID: 11520060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
    Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
    Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental expression of syndecan 1 is diminished in preeclampsia.
    Jokimaa VI; Kujari HP; Ekholm EM; Inki PL; Anttila L
    Am J Obstet Gynecol; 2000 Dec; 183(6):1495-8. PubMed ID: 11120517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence.
    Park PW; Pier GB; Hinkes MT; Bernfield M
    Nature; 2001 May; 411(6833):98-102. PubMed ID: 11333985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
    Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
    Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Syndecan recycling [corrected] is controlled by syntenin-PIP2 interaction and Arf6.
    Zimmermann P; Zhang Z; Degeest G; Mortier E; Leenaerts I; Coomans C; Schulz J; N'Kuli F; Courtoy PJ; David G
    Dev Cell; 2005 Sep; 9(3):377-88. PubMed ID: 16139226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.